According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A market access snapshot for Hep C treatment shows that commercial restrictions increased greatly over the past quarter while health exchange reimbursement lifted slightly during the same time period.
Source: MMIT data as of Q4 2016
Trends: A recent study that highlighted the physician perspective on Hepatitis C prescribing reveals that some HCPs question the level of restriction on current payer and PBM reimbursement. The concept of only paying for the sickest patients means that many of those suffering from Hep C never obtain access to the cures. Due to the high cost of treatment, coverage is essentially required.
In the full Reality Check on Hep C treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.
To read the full Reality Check on Hepatitis C treatments with key findings on clinical characteristics, Hep C drug market access and payer coverage, please click on the button below: